Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KPI Therapeutics working to develop effective, safe therapies for autoimmune diseases
April 2016
SHARING OPTIONS:

KPI Therapeutics
 
Dalazatide is a novel therapy targeting autoimmune diseases utilizing a new mechanism of action. Dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel implicated in many autoimmune diseases. Dalazatide is being studied as a potential lupus therapy. Peptides from the dalazatide family also have potential as therapies for uveitis and atopic dermatitis.
 
KPI Therapeutics
206-788-4600

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.